ArticleCancers2022
Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Clinicopathological differences and risk factors of early- versus late-onset pancreatic cancer: A systematic review and meta-analysis.iScience · 2026Article
- Pancreatic Neuroendocrine and Exocrine Cancer Incidence, and Stage at Diagnosis Before, During, and After the COVID-19 Pandemic, United States, 2019-2022.Journal of registry management · 2026Article
- Temporal trends in cross-country inequalities of early-onset pancreatic cancer: a comprehensive analysis for the global burden of disease study 2021.Scientific reports · 2025Article
- Trends in cancer mortality under age 50 in 15 upper-middle and high-income countries.Journal of the National Cancer Institute · 2025Article
- Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 2030.Frontiers in oncology · 2025Article
- Changes in the epidemiological trends of primary liver cancer in the Asia-Pacific region.Scientific reports · 2024Article
- Review
- Treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer.World journal of gastroenterology · 2024Article
- The microbiome and rise of early-onset cancers: knowledge gaps and research opportunities.Gut microbes · 2023Review
- Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer.JCO precision oncology · 2023Article
- Pancreatic cancer in young adults - an evolving entity?American journal of cancer research · 2023Review
- Shifting tides: the rising tide of early-onset cancers demands attention.BMJ oncology · 2023Article
- Clinical characteristics, treatment patterns and survival outcomes of early-onset pancreatic adenocarcinoma: a population-based study.American journal of translational research · 2023Article
- Article
- International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis.World journal of gastroenterology · 2022Article
- Early-Onset Cancers in Adults: A Review of Epidemiology, Supportive Care Needs and Future Research Priorities.Cancers · 2022Review
- Article
- Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-onset pancreatic cancer (EOPC) is relatively uncommon. It is unclear if the incidence of EOPC is evolving and how these patients are treated.
methodsWe conducted a retrospective, population-based study using SEER 2004-2016. We evaluated annual age-adjusted incidence rate (AAIR), stage at presentation, and race/ethnicity among 7802 patients plus treatment patterns in 7307 patients (excluding neuroendocrine tumors) younger than 50.
resultsThe AAIR was higher in males while the rate increased faster in females. The AAIR was highest in Non-Hispanic Black patients and increased for all races/ethnicities over time. The percentage of patients diagnosed with distant-stage disease decreased over time but increased for localized-stage disease. Hispanic patients made up a larger proportion of patients over time compared to other groups. For localized-stage disease, primary surgery alone was the most utilized modality of therapy. For regional-stage disease, chemotherapy with radiation was the most utilized modality from 2004-2010, whereas chemotherapy alone was the most utilized from 2011-2016. For distant-stage disease, chemotherapy alone was the most utilized and used increasingly over time. Patients with EOPC received radiation and chemotherapy at similar rates to, and underwent surgery more frequently, than patients 50-69.
conclusionsThe AAIR of EOPC increased over time, faster so in females. Groups who experience a higher burden of pancreatic cancer, particularly African Americans, experienced a higher burden of EOPC. Treatment of localized and regional-stage disease did not follow standard treatment guidelines for pancreatic cancer. Our findings indicate that EOPC patients received more treatment than their older counterparts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.